Review on the Protective Activity of Osthole Against the Pathogenesis of Osteoporosis

Overview

Journal Front Pharmacol

Date 2023 Sep 8

PMID 37680712

Authors

Jincai Chen

Xiaofei Liao

Juwen Gan

Affiliations

Soon will be listed here.

Abstract

Osteoporosis (OP), characterized by continuous bone loss and increased fracture risk, has posed a challenge to patients and society. Long-term administration of current pharmacological agents may cause severe side effects. Traditional medicines, acting as alternative agents, show promise in treating OP. Osthole, a natural coumarin derivative separated from (L.) Cusson and Maxim. f., exhibits protective effects against the pathological development of OP. Osthole increases osteoblast-related bone formation and decreases osteoclast-related bone resorption, suppressing OP-related fragility fracture. In addition, the metabolites of osthole may exhibit pharmacological effectiveness against OP development. Mechanically, osthole promotes osteogenic differentiation by activating the Wnt/β-catenin and BMP-2/Smad1/5/8 signaling pathways and suppresses RANKL-induced osteoclastogenesis and osteoclast activity. Thus, osthole may become a promising agent to protect against OP development. However, more studies should be performed due to, at least in part, the uncertainty of drug targets. Further pharmacological investigation of osthole in OP treatment might lead to the development of potential drug candidates.

Citing Articles

Osthole ameliorates wear particle-induced osteogenic impairment by mitigating endoplasmic reticulum stress via PERK signaling cascade.

Yu X, Jiang J, Li C, Wang Y, Ren Z, Hu J Mol Med. 2024; 30(1):266.

PMID: 39707212 PMC: 11660672. DOI: 10.1186/s10020-024-01034-z.

Anticancer potential of osthole: targeting gynecological tumors and breast cancer.

Han Y, Sun Z Pharmacol Rep. 2024; 77(1):87-102.

PMID: 39617816 DOI: 10.1007/s43440-024-00685-3.

Liuwei Dihuang Pills Enhance Osteogenic Differentiation in MC3T3-E1 Cells through the Activation of the Wnt/β-Catenin Signaling Pathway.

Zhao J, Liang G, Yang J, Huang H, Dou Y, Gu Z Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256932 PMC: 10819701. DOI: 10.3390/ph17010099.

References

Chen Y, Sun Y, Xue X, Ma H . Comprehensive analysis of epigenetics mechanisms in osteoporosis. Front Genet. 2023; 14:1153585. PMC: 10087084. DOI: 10.3389/fgene.2023.1153585. View

Silva B, Bilezikian J . Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism. Rev Endocr Metab Disord. 2020; 22(4):789-802. DOI: 10.1007/s11154-020-09614-0. View

Kuo P, Hsu Y, Chang C, Chang J . Osthole-mediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway in human osteoblast cells. J Pharmacol Exp Ther. 2005; 314(3):1290-9. DOI: 10.1124/jpet.105.085092. View

Tang D, Hou W, Zhou Q, Zhang M, Holz J, Sheu T . Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res. 2010; 25(6):1234-45. PMC: 3153131. DOI: 10.1002/jbmr.21. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Du R, Xue J, Wang H, Zhang Y, Xie M . Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression. Eur J Pharmacol. 2011; 666(1-3):183-8. DOI: 10.1016/j.ejphar.2011.05.014. View

Bonjour J, Benoit V, Pourchaire O, Ferry M, Rousseau B, Souberbielle J . Inhibition of markers of bone resorption by consumption of vitamin D and calcium-fortified soft plain cheese by institutionalised elderly women. Br J Nutr. 2009; 102(7):962-6. DOI: 10.1017/S0007114509371743. View

Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B . New horizons in treatment of osteoporosis. Daru. 2017; 25(1):2. PMC: 5297185. DOI: 10.1186/s40199-017-0167-z. View

Jia T, Wang H, Xie L, Wang X, Zhang R . Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem Pharmacol. 2003; 65(5):709-15. DOI: 10.1016/s0006-2952(02)01585-x. View

10.

Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure R . Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today. 2013; 19(3):204-8. PMC: 3979969. DOI: 10.1016/j.drudis.2013.07.015. View

11.

Ahn S, Lee Y, Hong S, Park J, Jeon Y, Yoo B . Risk of Fractures in Thyroid Cancer Patients With Postoperative Hypoparathyroidism: A Nationwide Cohort Study in Korea. J Bone Miner Res. 2023; 38(9):1268-1277. DOI: 10.1002/jbmr.4871. View

12.

Tsai T, Tsai T, Chen C, Chen C . Pharmacokinetics of osthole in rat plasma using high-performance liquid chromatography. J Pharm Biomed Anal. 1996; 14(6):749-53. DOI: 10.1016/0731-7085(95)01692-9. View

13.

Xiao P, Zhu Z, Du C, Zeng Y, Liao J, Cheng Q . Silencing Smad7 potentiates BMP2-induced chondrogenic differentiation and inhibits endochondral ossification in human synovial-derived mesenchymal stromal cells. Stem Cell Res Ther. 2021; 12(1):132. PMC: 7885459. DOI: 10.1186/s13287-021-02202-2. View

14.

Zheng X, Yu Y, Shao B, Gan N, Chen L, Yang D . Osthole improves therapy for osteoporosis through increasing autophagy of mesenchymal stem cells. Exp Anim. 2019; 68(4):453-463. PMC: 6842796. DOI: 10.1538/expanim.18-0178. View

15.

Dan J, Tan T, Wu M, Gong J, Yang Q, Wang L . Lithium chloride promotes diabetic corneal epithelial wound healing by activating the Wnt/β‑catenin signaling pathway. Exp Ther Med. 2023; 26(2):373. PMC: 10320653. DOI: 10.3892/etm.2023.12072. View

16.

Huo S, Yue B . Approaches to promoting bone marrow mesenchymal stem cell osteogenesis on orthopedic implant surface. World J Stem Cells. 2020; 12(7):545-561. PMC: 7415248. DOI: 10.4252/wjsc.v12.i7.545. View

17.

Lv S, Zhang Y, Yan M, Mao H, Pan C, Gan M . Inhibition of osteolysis after local administration of osthole in a TCP particles-induced osteolysis model. Int Orthop. 2015; 40(7):1545-52. DOI: 10.1007/s00264-015-3021-2. View

18.

Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U . Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res. 2003; 18(2):260-9. DOI: 10.1359/jbmr.2003.18.2.260. View

19.

Li X, Hara I, Matsumiya T . Effects of osthole on postmenopausal osteoporosis using ovariectomized rats; comparison to the effects of estradiol. Biol Pharm Bull. 2002; 25(6):738-42. DOI: 10.1248/bpb.25.738. View

20.

Yue Y, Li Y, Fu S, Wu Y, Zhu L, Hua L . Osthole inhibits cell proliferation by regulating the TGF-β1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells. Biomed Pharmacother. 2019; 121:109640. DOI: 10.1016/j.biopha.2019.109640. View